These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32166311)

  • 21. HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.
    Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV
    Curr HIV/AIDS Rep; 2017 Jun; 14(3):110-121. PubMed ID: 28432579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population.
    Stevens ER; Nucifora KA; Hagan H; Jordan AE; Uyei J; Khan B; Dombrowski K; des Jarlais D; Braithwaite RS
    Clin Infect Dis; 2020 Jun; 70(12):2652-2662. PubMed ID: 31400755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Creating an environment for equitable access to direct-acting antiviral therapy for people who inject drugs with hepatitis C.
    Dore GJ; Valerio H; Grebely J
    Liver Int; 2020 Oct; 40(10):2353-2355. PubMed ID: 33021345
    [No Abstract]   [Full Text] [Related]  

  • 24. Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs.
    Midgard H; Finbråten AK; Malme KB; Berg-Pedersen RM; Tanum L; Olsen IC; Bjørnestad R; Dalgard O
    Trials; 2020 Jun; 21(1):524. PubMed ID: 32539853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-reported outcomes of the Treatment and Prevention Study: A real-world community-based trial of direct-acting antivirals for hepatitis C among people who inject drugs.
    Goutzamanis S; Spelman T; Harney B; Dietze P; Stoove M; Higgs P; Thompson A; Doyle JS; Hellard M
    J Viral Hepat; 2021 Jul; 28(7):1068-1077. PubMed ID: 33880820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Barriers to antiviral treatment in hepatitis C infected intravenous drug users.
    Gazdag G; Horvath G; Szabo O; Ungvari GS
    Neuropsychopharmacol Hung; 2010 Dec; 12(4):459-62. PubMed ID: 21220790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
    Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH; Marks P; Quiene S; Siriragavan S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Dillon JF; Read P; Gane E; Dore GJ;
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):153-161. PubMed ID: 29310928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C virus reinfection following treatment among people who use drugs.
    Grady BP; Schinkel J; Thomas XV; Dalgard O
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S105-10. PubMed ID: 23884057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peer to peer communication about hepatitis C treatment amongst people who inject drugs: A longitudinal qualitative study.
    Goutzamanis S; Doyle JS; Horyniak D; Higgs P; Hellard M;
    Int J Drug Policy; 2021 Jan; 87():102983. PubMed ID: 33126166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs.
    Wade AJ; Doyle JS; Gane E; Stedman C; Draper B; Iser D; Roberts SK; Kemp W; Petrie D; Scott N; Higgs P; Agius PA; Roney J; Stothers L; Thompson AJ; Hellard ME
    Clin Infect Dis; 2020 Apr; 70(9):1900-1906. PubMed ID: 31233117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
    Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J;
    Int J Drug Policy; 2017 Sep; 47():230-238. PubMed ID: 28633998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era.
    Falade-Nwulia O; Sulkowski MS; Merkow A; Latkin C; Mehta SH
    J Viral Hepat; 2018 Mar; 25(3):220-227. PubMed ID: 29316030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reinfection with hepatitis C virus following sustained virological response in injection drug users.
    Grebely J; Knight E; Ngai T; Genoway KA; Raffa JD; Storms M; Gallagher L; Krajden M; Dore GJ; Duncan F; Conway B
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1281-4. PubMed ID: 20594256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Harm reduction-based and peer-supported hepatitis C treatment for people who inject drugs in Georgia.
    Kikvidze T; Luhmann N; Avril E; Butsashvili M; Labartkava K; Etienne A; Le Pluart D; Inaridze I; Gamezardashvili A; Kharshiladze D; Bouscaillou J
    Int J Drug Policy; 2018 Feb; 52():16-19. PubMed ID: 29227878
    [No Abstract]   [Full Text] [Related]  

  • 35. Low rate of reinfection among a cohort of people who use drugs successfully treated for hepatitis C virus infection in Vancouver, Canada.
    Holeksa J; Magel T; Alimohammadi A; Thiam A; Yung R; Chu L; Truong D; Conway B
    Int J Drug Policy; 2019 Oct; 72():177-180. PubMed ID: 31176594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age-Related Differences in Past or Present Hepatitis C Virus Infection Among People Who Inject Drugs: National Human Immunodeficiency Virus Behavioral Surveillance, 8 US Cities, 2015.
    Abara WE; Trujillo L; Broz D; Finlayson T; Teshale E; Paz-Bailey G; Glick S; Al-Tayyib AA; Robinson WT; Masiello-Schuette S; Sey EK; Anderson BJ; Poe J; Braunstein S
    J Infect Dis; 2019 Jul; 220(3):377-385. PubMed ID: 30915477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmaceutical citizenship in an era of universal access to hepatitis C treatment: Situated potentials and limits.
    Rance J; Rhodes T; Lancaster K
    Health (London); 2022 Nov; 26(6):736-752. PubMed ID: 33506718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units.
    Valencia J; Alvaro-Meca A; Troya J; Cuevas G; Gutiérrez J; Morro A; Alvarez J; Pulido L; Cañamares I; Escobar I; Moreno S; Ryan P
    Int J Drug Policy; 2019 Oct; 72():181-188. PubMed ID: 31253391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Examination of the risk of reinfection with hepatitis C among injecting drug users who have been tested in Glasgow.
    McDonald SA; Hutchinson SJ; Cameron SO; Innes HA; McLeod A; Goldberg DJ
    Int J Drug Policy; 2012 Sep; 23(5):353-7. PubMed ID: 22421553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C Virus Treatment and Persons Who Inject Drugs.
    Grebely J; Dore GJ; Greenwald R; Swan T; Barua S; Taylor LE
    Ann Intern Med; 2016 Feb; 164(3):203. PubMed ID: 26829914
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.